STAR-T cell therapy for progressive multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new cell therapy called STAR-T, which uses your own immune cells to target and attack the faulty immune cells that cause multiple sclerosis (MS). It aims to slow or stop the disease in people who have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with multiple sclerosis (MS), including progressive or relapsing-remitting forms.
- Your disability level is moderate, measured by a score between 2 and 7 on the EDSS scale.
- You have tried at least one MS treatment that didn't work, or you've had recent relapses or new brain lesions.
- Your liver, kidney, and blood counts are within safe limits for the study.
- You agree to use birth control or abstain from sex during the study and for 12 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called STAR-T cells for adults with generalized myasthenia gravis whose symptoms are not well controlled with current treatments. The goal is to stop the immune system from attacking the body's own tissues, which might reduce muscle weakness.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
This trial uses your own blood stem cells to reboot your immune system, which may help stop multiple sclerosis attacks and slow disability. It is for people with active MS that has not responded well to other treatments.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
Hear when a new Multiple Sclerosis (MS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.